Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2017

Open Access 01-12-2017 | Research

Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma

Authors: Rachel Caswell-Smith, Terrianne Cripps, Thom Charles, Alexander Hosking, Meghana Handigol, Cecile Holweg, John Matthews, Mark Holliday, Corentin Maillot, James Fingleton, Mark Weatherall, Richard Beasley, Irene Braithwaite, On behalf of the Periostin Study Team

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2017

Login to get access

Abstract

Background

We aimed to determine the effect of sampling time during the day on serum periostin levels in adult participants with and without asthma.

Methods

Serum periostin was measured at 2-h intervals from 0800 to 1800 h in 16 adult participants with stable asthma prescribed inhaled corticosteroid and long-acting beta-agonist therapy, and in 16 otherwise healthy participants without asthma. Mixed linear models were used to compare time zero (08:00 h) with subsequent measurement time for serum periostin for both groups.

Results

In both asthma and non-asthma, the mean (SD) serum periostin levels continuously reduced during the day from 53.5 (13.6) ng/mL at 0800 h to 50.9 (13.4) ng/mL at 1800 h (difference log periostin −0.05, P ≤ 0.001) and 50.5 (13.0) ng/mL at 0800 h to 46.2 (11.5) ng/mL at 1800 h (difference log periostin −0.08, P ≤ 0.001) respectively.

Conclusions

Periostin values are higher in the morning compared with the afternoon in asthmatic and non-asthmatic adults. The small magnitude of the variation in serum periostin levels suggests that the time of day in which the serum periostin measurements are made is unlikely to influence treatment decisions if a specific serum periostin level is used to predict treatment responsiveness.
Trial registration Australia New Zealand Trials Registry (ACTRN12614000072617)
Appendix
Available only for authorised users
Literature
1.
2.
3.
Taylor DR. Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol. 2011;128:927–34.CrossRefPubMed
4.
Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA Jr, Schleimer RP, Minnicozzi M. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012;129(Suppl 3):S9–23.CrossRefPubMedPubMedCentral
5.
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95.CrossRefPubMedPubMedCentral
6.
Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR. Bronchoscopic exploratory research study of biomarkers in corticosteroid-refractory asthma (BOBCAT) study group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012;130:647–54.CrossRefPubMedPubMedCentral
7.
Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, McKenzie AN, Nagai H, Hotokebuchi T, Izuhara K. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118:98–104.CrossRefPubMed
8.
Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA. 2007;104:15858–63.CrossRefPubMedPubMedCentral
9.
Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–98.CrossRefPubMed
10.
Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804–11.CrossRefPubMed
11.
Wenzel S, Swanson B, Teper A, Hamilton J, Izuhara K, Ohta S, et al. Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients. Eur Respir J. 2016;48(Suppl 60):1798.CrossRef
12.
Caswell-Smith R, Hosking A, Cripps T, Holweg C, Matthews J, Holliday M, Maillot C, Fingleton J, Weatherall M, Beasley R. Reference ranges for serum periostin in a population without asthma or COPD. Clin Exp Allergy. 2016. doi:10.​1111/​cea.​12763.PubMed
13.
Fingleton J, Braithwaite I, Travers J, Bowles D, Strik R, Siebers R, Holweg C, Matthews J, Weatherall M, Beasley R, NZRHS Study Group. Serum periostin in obstructive airways disease: distribution, relationships, and steroid responsiveness. Eur Resp J. 2016. doi:10.​1183/​13993003.​01384-2015.
14.
Panzer SE, Dodge AM, Kelly EA, Jarjour NN. Circadian variation of sputum inflammatory cells in mild asthma. J Allergy Clin Immunol. 2003;111:308–12.CrossRefPubMed
15.
Kelly EA, Houtman JJ, Jarjour NN. Inflammatory changes associated with circadian variation in pulmonary function in subjects with mild asthma. Clin Exp Allergy. 2004;34:227–33.CrossRefPubMed
16.
Wempe JB, Tammeling EP, Koeter GH, Hakansson L, Venge P, Postma DS. Blood eosinophil numbers and activity during 24 h: effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol. 1992;90:757–65.CrossRefPubMed
17.
Winkel P, Statland BE, Saunders AM, Osborn H, Kupperman H. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol. 1981;75:693–700.CrossRefPubMed
18.
Uhrbrand H. The number of circulating eosinophils; normal figures and spontaneous variations. Acta Med Scand. 1958;160:99–104.CrossRefPubMed
19.
Pijnenburg MW, Floor SE, Hop WC, De Jongste JC. Daily ambulatory exhaled nitric oxide measurements in asthma. Pediatr Allergy Immunol. 2006;17:189–93.CrossRefPubMed
20.
ten Hacken NH, van der Vaart H, van der Mark TW, Koeter GH, Postma DS. Exhaled nitric oxide is higher both at day and night in subjects with nocturnal asthma. Am J Respir Crit Care Med. 1998;158:902–7.CrossRefPubMed
21.
Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar PK, Chung KF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. Eur Respir J. 2014;43:474–84.CrossRefPubMed
22.
Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.CrossRefPubMedPubMedCentral
23.
Offline NO. ATS/ERS Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med. 2005;171:912–30.CrossRef
24.
Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed
25.
Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553–8.CrossRefPubMed
26.
Juniper EF, Bousquet J, Abetz L, Bateman ED. The GOAL committee identifying ‘well controlled’ and ‘not well controlled’ asthma using the Asthma Control Questionnaire. Respir Med. 2006;100:616–21.CrossRefPubMed
27.
Palme S, Christenson RH, Jortani SA, Ostlund RE, Kolm R, Kopal G, Laubender RP. Multicenter evaluation of analytical characteristics of the Elecsys® periostin immunoassay. Clin Biochem. 2016.
28.
29.
Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR. Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J. 2002;20:601–8.CrossRefPubMed
30.
Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest. 2008;133:1232–42.CrossRefPubMed
31.
Shaw DE, Wilson E, Pavord ID. Exhaled nitric oxide in asthma. In: European respiratory monograph: ERS 2010;49 Chapter 2:32–44.
Metadata
Title
Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma
Authors
Rachel Caswell-Smith
Terrianne Cripps
Thom Charles
Alexander Hosking
Meghana Handigol
Cecile Holweg
John Matthews
Mark Holliday
Corentin Maillot
James Fingleton
Mark Weatherall
Richard Beasley
Irene Braithwaite
On behalf of the Periostin Study Team
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2017
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-017-0182-0

Other articles of this Issue 1/2017

Allergy, Asthma & Clinical Immunology 1/2017 Go to the issue

Research

Expression of intelectin-1 in bronchial epithelial cells of asthma is correlated with T-helper 2 (Type-2) related parameters and its function

Research

Prediction of clinical peanut allergy status among children in Hamilton, Ontario using chart review data collected during 2012–2015

Research

Oral food challenge outcomes in a pediatric tertiary care center

Short report

Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36

Case report

Serum free IgE guided dose reduction of omalizumab: a case report

Research

Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies